Alemtuzumab

Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors

Retrieved on: 
Thursday, April 4, 2024
Neurology, Sanofi, Alemtuzumab, Myelin, Public health, Growth, Massachusetts General Hospital, Multiple sclerosis, University, Patient, Research, Inflammation, Biology, Interferon beta-1a, MPH, Brigham and Women's Hospital, DSM-IV codes, Hospital, Drug development, Natalizumab, Rheumatology, Pharmaceutical industry

He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company.

Key Points: 
  • He also serves on the board of directors of Athira Pharma, Inc., a neurology-focused clinical-stage biopharmaceutical company.
  • "We are delighted to welcome Dr. Panzara to our board of directors," said Dr. Carol Curtis, chief executive officer of Cadenza Bio.
  • "His extensive experience in developing therapies for MS and other neurological disorders aligns perfectly with our mission at Cadenza Bio.
  • "I look forward to joining the board of directors at Cadenza Bio at such an exciting time in the growth of the company," said Dr. Panzara.

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Patient, Cyclophosphamide, Infrared spectroscopy correlation table, Graft-versus-host disease, CD19, CD22, CDMO, Society, Neurotoxicity, ASH, Alemtuzumab, Hematology, Euronext Growth, San Diego Convention Center, Clinical trial, Cytokine release syndrome, Relapse, DLT, Allotransplantation, B-ALL, NHL, CRS, FCA, Investigational New Drug, Pharmaceutical industry, Medical device, Cosmetics, Vaccine

Cytokine release syndrome (CRS) Grade 1 or 2 occurred in all patients, and all CRS resolved with treatment.

Key Points: 
  • Cytokine release syndrome (CRS) Grade 1 or 2 occurred in all patients, and all CRS resolved with treatment.
  • No immune effector cell associated neurotoxicity (ICANS) or graft versus host disease (GvHD) was observed.
  • There were no UCART20x22 dose limiting toxicities (DLTs), and there was 1 DLT in connection with CLLS52 (alemtuzumab).
  • The study continues to enroll patients at dose level 2i (2.5 million cells/kg) with UCART22 P2.

Lexicon Strengthens Management Team With Two New Executives

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, National Investor Relations Institute, Professional corporation, Bristol Myers Squibb, Melinta Therapeutics, Policy, AbbVie, Lexicon, Therapy, Ophthalmology, Actavis, Intercept, BS, Seton Hall University, Ozanimod, University, Amarin, Warner Chilcott, MBA, Ladenburg Thalmann, Alemtuzumab, Allergan, Business administration, Marketing, Wall Street, Watson Labs, Villalba v Merrill Lynch & Co Inc, Sclerosis, Heart failure, Intercept Pharmaceuticals, Pharmaceutical industry

THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.

Key Points: 
  • Mr. Cullen brings Lexicon more than 35 years of industry experience in market access and sales leadership.
  • Before joining Lexicon, Matt served as vice president, value, access and policy at Apellis Pharmaceuticals where he led the market access launch of rare disease drug EMPAVELI® (pegcetacoplan) and ophthalmology drug SYFOVRE® (pegcetacoplan injection).
  • His responsibilities included pricing and contracting, payer strategy and marketing, corporate and strategic account management, field reimbursement, trade and distribution, and training.
  • Prior to Apellis, Mr. Cullen led strategic payer marketing and access teams at Bristol-Myers Squibb for ELIQUIS® (apixaban) and ORENCIA® (abatacept).

Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023

Retrieved on: 
Friday, June 9, 2023
Graft-versus-host disease, Euronext Growth, Febrile neutropenia, ASH, CD19, European Hematology Association, ALC, CRS, Infection, Venetoclax, Clinical trial, Skin, Cyclophosphamide, FC, Acute promyelocytic leukemia, HSCT, Șaeș, MRD, CAR, Cytokine release syndrome, Patient, DLI, EHA, Alemtuzumab, Host, CRi, CR, FCA, Infrared spectroscopy correlation table, Society, Blinatumomab, Hematopoietic stem cell transplantation, Safety, Vaccine, Medical device, Medical imaging

NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated clinical and translational data on its clinical trial BALLI-01 (evaluating UCART22) at the European Hematology Association (EHA) 2023.

Key Points: 
  • NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated clinical and translational data on its clinical trial BALLI-01 (evaluating UCART22) at the European Hematology Association (EHA) 2023.
  • The data presented support the preliminary safety and efficacy of UCART22 in a heavily pretreated relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) population.
  • UCART22 cell expansion was detected in 9 of 13 patients in the FCA LD arm and associated with clinical activity.
  • Overall, these data support the preliminary safety and efficacy of UCART22 in this heavily pretreated r/r B-ALL population.

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

Retrieved on: 
Wednesday, May 17, 2023
DNA, Euronext Growth, Arm, ASH, Gene, CRS, Relapse, Neoplasm, Gene editing, Bone marrow, UCART123, Cyclophosphamide, FC, Cmax, Allotransplantation, DL2, Acute myeloid leukemia, MRD, CAR, AML, Patient, AUC, Annual general meeting, Alemtuzumab, Cytokine release syndrome, Cell, TGFB1, CR, FCA, American Society of Gene and Cell Therapy, Multi, Infrared spectroscopy correlation table, Cell engineering, PD-1, Safety, Tumor microenvironment, Society, Disease, Vaccine, Pharmaceutical industry, Medical imaging, Cellectis

Cytokine release syndrome (CRS) occurred in eight patients in the FC arm and nine patients in the FCA arm.

Key Points: 
  • Cytokine release syndrome (CRS) occurred in eight patients in the FC arm and nine patients in the FCA arm.
  • The preclinical data demonstrate that multiplexed engineering does not compromise CAR T-cell function, which can even be enhanced and display improved anti-tumor activity.
  • These preclinical data show that we can precisely select and combine an array of gene and cell engineering approaches to produce armored CAR T-cells with high efficiency rates.
  • TALEN® and TALE-BE technologies can be integrated in the generation of CAR T-cells to provide high gene editing rates while preserving genomic safety.

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Retrieved on: 
Thursday, May 11, 2023
Graft-versus-host disease, TRAC, Euronext Growth, Assistance Publique–Hôpitaux de Paris, CD19, European Hematology Association, Relapse, CD52, Cyclophosphamide, FC, Allotransplantation, CAR, Patient, B-ALL, Risk, EHA, Alemtuzumab, FCA, Infrared spectroscopy correlation table, Safety, Vaccine, Pharmaceutical industry, Cellectis

“Cellectis is excited to present updated clinical and translational data from its BALLI-01 clinical trial (evaluating UCART22) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Key Points: 
  • “Cellectis is excited to present updated clinical and translational data from its BALLI-01 clinical trial (evaluating UCART22) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
  • The data show that UCART22 was well tolerated and clinical responses were achieved.
  • UCART22 continues to have a good safety profile, with no serious treatment emergent adverse events (TEAEs) or DLTs reported.
  • Overall, these data support the safety and preliminary efficacy of UCART22 in a heavily pretreated r/r B-ALL population.

Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Tuesday, May 2, 2023
Graft-versus-host disease, TRAC, Euronext Growth, ASH, Gene, Relapse, Neoplasm, LD, Gene editing, CD52, UCART123, Cyclophosphamide, FC, Allotransplantation, CAR, AML, Patient, Risk, Annual general meeting, Alemtuzumab, Cell, FCA, American Society of Gene and Cell Therapy, Society, Bone marrow, Vaccine, Cellectis

The data show that adding alemtuzumab to the FC regimen was associated with improved LD and significantly higher UCART123 cell expansion, which correlated with improved activity.

Key Points: 
  • The data show that adding alemtuzumab to the FC regimen was associated with improved LD and significantly higher UCART123 cell expansion, which correlated with improved activity.
  • However, additional physiological and biological barriers imposed by the hostile tumor microenvironment has limited the ability to target solid tumors.
  • This glimpse of success also demonstrated that we need to be able to creatively customize and equip CAR T-cells to target these tumors.
  • By carefully choosing a range of gene and cell engineering approaches, Cellectis can develop CAR T-cells focused on unmet medical needs with a high level of efficiency for gene editing and targeted-integration.

Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab

Retrieved on: 
Monday, April 24, 2023
Partnership, Euronext Growth, ASH, ALL, IMP, CD52, NHL, UCART123, CAR, AML, Alemtuzumab, Sanofi, Vaccine, Cellectis

In May 2021, Cellectis entered into partnership and supply agreements with Sanofi regarding alemtuzumab.

Key Points: 
  • In May 2021, Cellectis entered into partnership and supply agreements with Sanofi regarding alemtuzumab.
  • Under the agreements, Sanofi is supplying alemtuzumab to support Cellectis’ clinical trials and the parties agreed to enter into discussions to execute a commercial supply of alemtuzumab under pre-agreed financial conditions.
  • Cellectis is the inventor of the combination of CD52 knockout UCART cells with a lymphodepleting regimen containing an anti-CD52 antibody such as alemtuzumab.
  • The CD52 knockout aims to render UCART product candidates resistant to alemtuzumab as part of the lymphodepleting regimen.

Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22

Retrieved on: 
Tuesday, April 11, 2023
GMP, Toxicity, Euronext Growth, CD22, Cyclophosphamide, CAR, Patient, Alemtuzumab, FCA, Safety, Pharmaceutical industry, Cellectis

“Our team has worked tirelessly to expand our BALLI-01 clinical study (evaluating UCART22) to Europe.

Key Points: 
  • “Our team has worked tirelessly to expand our BALLI-01 clinical study (evaluating UCART22) to Europe.
  • Dosing our first patient in France with our UCART22 product candidate manufactured in-house is an important advancement for Cellectis,” said Mark Frattini, M.D., Ph.D., Chief Medical Officer at Cellectis.
  • UCART22 is currently the most advanced allogeneic CAR T-cell product in development for r/r B-cell ALL.
  • The BALLI-01 study (evaluating UCART22) is actively enrolling patients with r/r B-cell ALL after FCA lymphodepletion.

Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

Retrieved on: 
Tuesday, January 3, 2023
Bone marrow, Genetic distance, Melphalan, NHLBI, SCD, Busulfan, Therapy, Nominal interest rate, Sickle cell disease, Phenotype, Toxicity, Alemtuzumab, Cellular, Patient, Thalassemia, Beta thalassemia, Physician, Safety, B cell, Transplant, Cell, Dentistry

The addition of briquilimab is being studied as a potential way to achieve a higher percentage of healthy donor stem cell engraftment (donor chimerism) without increased toxicity.

Key Points: 
  • The addition of briquilimab is being studied as a potential way to achieve a higher percentage of healthy donor stem cell engraftment (donor chimerism) without increased toxicity.
  • The Phase 1/2 clinical study is led by Dr. John F. Tisdale, Director of the Cellular and Molecular Therapeutics Laboratory, NHLBI.
  • Briquilimab has the potential to improve disease-free survival in combination with low-dose irradiation as part of a transplant conditioning regimen.
  • All three sickle cell study participants treated with briquilimab have successfully engrafted with no briquilimab-related severe adverse events observed.